VV-ECMO Wins Big: Twice the Survival Odds Over VA-ECMO in Respiratory Failure

link.springer.com November 20, 2025

A PRISMA-guided systematic review and meta-analysis of 11 studies involving 3,598 patients with severe respiratory failure found that veno-venous ECMO (VV-ECMO) is linked to significantly better survival to hospital discharge than veno-arterial ECMO (VA-ECMO) in both adults (OR 1.90, 95% CI 1.32–2.75) and children (OR 2.01, 95% CI 1.03–3.95).

Despite VA-ECMO patients being markedly sicker at baseline (clear confounding by indication), VV-ECMO still came out ahead.

Adults on VV-ECMO also had shorter ICU stays by an average of 20 days and lower rates of hemolysis, though pediatric VV-ECMO patients showed a slightly higher risk of renal complications.

The authors conclude that VV-ECMO should be the default extracorporeal support strategy for isolated severe respiratory failure, with VA-ECMO reserved strictly for patients with refractory cardiogenic shock and clear cardiac involvement.